Wearable Data Shows Recovery Gaps After COVID-19, Flu, Strep

A 2026 study published in The Lancet Digital Health reports that patients recovering from COVID-19, influenza, and group A streptococcus often resume normal activity well before their bodies return to physiological baseline, revealing a measurable gap between perceived and biological recovery that could influence clinical guidance, digital health strategies, and insurance models.

The research, based on continuous smartwatch data and daily symptom reporting, identified what researchers termed a “digital recovery lag,” particularly pronounced in moderate to severe COVID-19 cases. According to the authors, reliance on self-reported symptoms alone may underestimate ongoing physiological stress after infection and contribute to premature returns to work, exercise, or normal routines.

The study followed 4,795 adults enrolled in Israel’s Maccabi Healthcare Services over a two-year period from November 2020 to May 2023. Participants, with a median age range between 38 and 51, wore Garmin Vivosmart 4 smartwatches that tracked heart rate, heart rate variability-based stress indicators, and physical activity. In parallel, participants completed daily symptom questionnaires through a dedicated mobile application. The researchers compared the point at which individuals reported being symptom-free with the moment their physiological indicators returned to pre-infection baselines.

Across all three infections studied, self-reported recovery consistently preceded physiological recovery. In mild COVID-19 cases, participants reported feeling better after an average of 8.5 days, while digital recovery occurred closer to 15 days. In moderate to severe COVID-19 cases, symptoms resolved after roughly 12 days, but heart rate and related markers did not normalize for an average of 72 days. Influenza showed shorter recovery lags, ranging from about 2.5 days in mild cases to nearly eight days in more severe cases. Group A streptococcus showed the shortest gap, with some mild cases returning to baseline physiology even before symptoms fully resolved.

Heart rate emerged as the most persistent indicator of incomplete recovery. During the acute phase of COVID-19, moderate to severe cases showed an average peak deviation of about six beats per minute above baseline. Even after symptoms ended, a smaller but statistically significant elevation persisted, representing sustained autonomic load. For moderate to severe COVID-19 cases, this translated into an estimated 75,000 additional heartbeats during the recovery period. Heart rate variability-based stress measures tended to normalize earlier, suggesting partial nervous system recovery even as cardiovascular strain remained.

The study also found a disconnect between behavior and physiology. On the day participants reported being symptom-free, their daily steps, distance walked, and active calories immediately returned to baseline levels. Researchers described this as a decoupling between how patients feel and how their bodies function, raising concerns that individuals may unknowingly place strain on systems that have not fully recovered. The authors note that resuming intense physical activity during this phase runs counter to expert guidance and may increase the risk of relapse, complications, or longer-term inflammatory effects.

The findings challenge symptom-based recovery guidelines that are widely used in clinical and workplace settings. Current recommendations often allow individuals to resume normal activities within 24 hours of fever resolution or symptom improvement. The study suggests that full physiological recovery may take about one week for group A streptococcus, two weeks for influenza, and up to two months for COVID-19, depending on severity. The authors argue that wearable data could provide a scalable, non-invasive way to tailor recovery guidance based on objective indicators rather than subjective perception alone.

The results also align with broader shifts underway in healthcare delivery, as medical devices and digital platforms expand beyond clinical settings into daily life. Wearables, remote monitoring tools, and connected medical devices are increasingly positioned as complements to traditional care, particularly in prevention, follow-up, and chronic disease management. “Medical devices are a vital element and will enable a quantum leap in the personal and general health sector,” says Gervasio Videla, Co-Founder, CEO, Ellie Care, a senior care platform that uses smartwatches to monitor adults over 65. Adoption, however, depends on healthcare systems balancing accessibility, quality, and cost while prioritizing technology within public and private budgets.

AI and data analytics are expected to amplify the impact of these devices. Maria Salido, CEO, Social Diabetes, says that the combination of wearables and AI could enable the detection of disease before symptoms appear, moving healthcare further toward prevention. Patrick Devlyn, President of The Health Commission, CCE, adds that AI and machine learning will become decisive across healthcare services and could help close social and economic gaps if adopted within open, interoperable systems.

Insurance providers are also examining how continuous physiological data could reshape risk assessment and coverage models. Eduardo Lara, Vice President of Health for Latin America, Reinsurance Group of America, says the pandemic highlighted the limits of traditional actuarial approaches based on historical data. He notes that smartwatches already allow doctors to monitor patients’ symptoms and behavior in real time, reducing risks such as cardiac failure and enabling more predictive models. According to Lara, the sector is gradually moving toward prospective methodologies that incorporate behavioral data, while emphasizing confidentiality and responsible use.

These developments intersect with broader debates around predictive and personalized medicine. Industry analysts note a shift from reactive care toward prevention as chronic diseases rise and healthcare costs increase. Continuous monitoring devices and digital platforms already collect large volumes of personal health data, creating new opportunities to model risk, guide interventions, and design more individualized care pathways. At the same time, experts warn that predictive systems raise ethical and regulatory questions, particularly around fairness, transparency and data governance.

In Mexico, digital health adoption has accelerated through telemedicine and online platforms, though structural gaps remain. Adrian Alcántara, CEO, Doctoralia Mexico, says the country’s healthcare system still operates largely in silos, limiting coordination and outcome measurement. With over 2 million appointments booked monthly on Doctoralia’s platform, he said behavioral data is already being used to improve patient-doctor matching and could support a transition toward predictive, experience-based care models if interoperability improves.

The Lancet study’s authors acknowledged limitations, including the use of consumer-grade devices, reliance on self-reported influenza tests, and recruitment through social media, which may limit generalizability. External factors such as caffeine intake or non-illness-related stress were not fully controlled. Despite these constraints, the researchers argued that the consistency of the findings across infections and severity levels supports the validity of digital recovery metrics as indicators of ongoing physiological burden.

As healthcare systems, employers, and insurers continue to integrate digital tools, the concept of recovery may require redefinition. The study suggests that symptom resolution does not necessarily signal full recovery and that wearable data can reveal hidden physiological strain that persists long after individuals feel well.